Cabaletta Bio (CABA) Reports Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy

Go back to Cabaletta Bio (CABA) Reports Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy
(NASDAQ: CABA) Delayed: 2.67 -0.18 (6.32%)
Previous Close $2.85    52 Week High
Open $2.83    52 Week Low
Day High $2.84    P/E N/A 
Day Low $2.66    EPS
Volume 24,500